Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VG 161

Next Previous
Drug Profile

VG 161

Alternative Names: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection; VG-161

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Virogin Biotech - China National Biotec Group (JV)
  • Developer Virogin Biotech; Virogin Biotech - China National Biotec Group (JV)
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 15 receptor alpha expression stimulants; Interleukin-12 expression stimulants; Interleukin-15 expression stimulants; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity No
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase II Cholangiocarcinoma; Liver cancer; Sarcoma
  • Phase I/II Gastric cancer; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 30 May 2025 Efficacy and adverse events data from phase-I/II trial in Liver cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Intratumoural, Injection)
  • 31 May 2024 Efficacy and adverse events data from phase-I trial in Liver cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top